Patients
Trials
Expanded Access
Pipeline
Zanidatamab
Zanidatamab Zovodotin
Preclinical & Advanced Discovery
Partnerships
Publications
Partners
Technology
Azymetric™
ZymeLink™
EFECT™
ProTECT™
Science
Careers
Apply
Perks & Benefits
Corporate Gallery
About
Leadership
Board of Directors
News
Investors & Media
News
Zymeworks Announces Oral Presentation Of Data From Phase 1 Study Of Zanidatamab Zovodotin (ZW49) In Solid Cancers At European Society For Medical Oncology (ESMO) Congress 2022 In Paris
Jul 25, 2022
Back